Recently, Dingzhi Dental, a leading brand and expert in complex dental implants in China, announced the closing of its Series A financing, raising several hundred million RMB, with Eight Roads as the sole investor. CEC Capital served as the exclusive
Wuhan-based iRegene, which aims to become a global leader in universal chemically induced cell therapy, recently announced the closing of its Series B financing, raising several hundred million RMB. The round was co-led by Orinno Capital and CDBT Group, w
MicroCyto announced that it has raised over 300 million yuan in Series A financing. The round was led by Beijing Jingguorui Investment, with participation from Beijing Medical and Health Industry Investment Fund, Shenzhen Capital Group, and Hebei Producti
MoonBiotech announced that it has recently completed a RMB 300 million Series C+ financing, solely invested by SDIC JULI Investment Management Co., LTD. This financing round follows the Series C funding involving SDIC Venture Capital, marking another inst
Recently, Blue Sail Medical (002382.SZ) announced that its cardiovascular and cerebrovascular business unit, Blue Sail Biosensors, has raised a total of RMB 1 billion in funding. The Series A2 round introduced an additional RMB 100 million, following a RM
Recently, Vision Medicals announced a successful completion of D+ round funding worth hundreds of millions RMB, with Kequan Fund as lead-investor and Tianxin Fund as co-investor. Funds raised in this round will be primarily used to promote the research an
Recently, InfiMotion announced the completion of hundreds of millions of yuan in Series A funding. The round was led by the National Adjustment Fund, with participation from Wuxi New Energy Industry Fund, Huiheng Industry, Huishan Financial Services, and
On February 21, 2024, Yantai Dongcheng Biochemicals (002675) announced that its wholly-owned subsidiary, Yitai Pharmaceutical, intends to purchase the 99mTc-GSA injection and GSA cold kit (hereinafter referred to as the "target product") held by Rongcheng